|
|
|
xiii | |
| Foreword |
|
xxii | |
| Preface |
|
xxiv | |
| Acknowledgments |
|
xxv | |
|
|
|
|
1 Prostate cancer: the last twenty years |
|
|
3 | (4) |
|
|
|
|
|
7 | (16) |
|
|
|
|
|
|
|
3 Risk factors for prostate cancer: diet and lifestyle studies |
|
|
23 | (10) |
|
|
|
|
|
4 Molecular epidemiology of prostate cancer |
|
|
33 | (10) |
|
|
|
|
|
5 Applications of gene array technology to prostate cancer |
|
|
43 | (10) |
|
|
|
6 Topographic anatomy of prostate, seminal vesicles, vas deferens, and ejaculatory ducts |
|
|
53 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
7 Prostate physiology and function |
|
|
63 | (12) |
|
|
|
|
|
8 Neuroanatomy and neuroregulation of the prostate |
|
|
75 | (10) |
|
|
|
|
|
9 Androgens and the androgen receptor in normal prostate |
|
|
85 | (6) |
|
|
|
10 Growth factor signaling in the regulation of prostate growth |
|
|
91 | (14) |
|
|
|
|
|
|
|
SECTION 2 Pathology of prostate cancer |
|
|
|
11 Histopathology of prostate cancer and pathologic staging |
|
|
105 | (12) |
|
|
|
12 Precursor lesions of prostatic adenocarcinoma |
|
|
117 | (8) |
|
|
|
13 Pathologic characteristics of soft tissue and osseous metastases |
|
|
125 | (10) |
|
|
|
|
|
14 Non-adenocarcinomatous cancers of the prostate |
|
|
135 | (8) |
|
|
|
15 Neuroendocrine differentiation in prostate cancer |
|
|
143 | (8) |
|
|
|
|
|
P. Anthony di Sant'Agnese |
|
|
16 New concepts in the molecular pathology of prostate cancer |
|
|
151 | (20) |
|
|
|
|
|
|
|
SECTION 3 Etiology of prostate cancer |
|
|
|
17 Concepts in etiology of prostate cancer |
|
|
171 | (10) |
|
|
|
|
|
|
|
18 Obesity and prostate cancer |
|
|
181 | (10) |
|
|
|
|
|
19 Chemoprevention of prostate cancer: concepts and evidence |
|
|
191 | (10) |
|
|
|
20 Molecular aspects of chemoprevention of prostate cancer |
|
|
201 | (12) |
|
|
|
21 Testosterone and prostate safety |
|
|
213 | (10) |
|
|
|
22 Vitamin D, retinoids, and prostate cancer |
|
|
223 | (8) |
|
|
|
SECTION 4 Molecular mechanisms of prostate carcinogenesis |
|
|
|
23 Mechanisms of prostate cancer progression |
|
|
231 | (8) |
|
|
|
|
|
24 Inherited susceptibility for prostate cancer - family and case-control studies |
|
|
239 | (10) |
|
|
|
|
|
|
|
|
|
25 Prostate cancer stem cells |
|
|
249 | (10) |
|
|
|
|
|
|
|
|
|
26 Rationale for molecular markers of prostate cancer |
|
|
259 | (10) |
|
|
|
|
|
|
|
27 Molecular biology of serum biomarkers for prostate cancer |
|
|
269 | (16) |
|
|
|
28 Molecular biology of tissue biomarkers for prostate cancer |
|
|
285 | (22) |
|
|
|
|
|
29 Biologic response modifiers and prostate cancer |
|
|
307 | (12) |
|
|
|
|
|
30 Cell adhesion molecules in prostate cancer |
|
|
319 | (6) |
|
|
|
31 Apoptosis and prostate cancer |
|
|
325 | (8) |
|
|
|
|
|
|
|
|
|
32 Cellular proliferation and senescence in prostate cancer |
|
|
333 | (12) |
|
|
|
|
|
33 Angiogenesis and prostate cancer |
|
|
345 | (8) |
|
|
|
|
|
34 Endothelin and prostate cancer |
|
|
353 | (8) |
|
|
|
35 Mechanisms of androgen independence |
|
|
361 | (8) |
|
|
|
|
|
36 Knockout models of prostate carcinogenesis |
|
|
369 | (14) |
|
|
|
|
|
37 Molecular mechanisms of metastasis in prostate cancer |
|
|
383 | (18) |
|
|
|
|
|
38 Novel targets for prostate cancer immunotherapy |
|
|
401 | (14) |
|
|
|
|
|
SECTION 5 Clinical diagnosis and staging of prostate cancer |
|
|
|
39 New concepts in the early detection of prostate cancer |
|
|
415 | (12) |
|
|
|
|
|
40 Screening for prostate cancer: the ERSPC study |
|
|
427 | (8) |
|
|
|
41 Screening for prostate cancer and its effect on mortality: the Tyrol study |
|
|
435 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42 Lessons from the prostate cancer awareness week program and PLCO study |
|
|
441 | (6) |
|
|
|
|
|
43 Clinical staging of prostate cancer: an overview |
|
|
447 | (12) |
|
|
|
|
|
44 TNM and IUCC staging of prostate cancer |
|
|
459 | (8) |
|
|
|
|
|
|
|
45 Prostate-specific antigen: practical applications and future prospects |
|
|
467 | (12) |
|
|
|
|
|
46 Clinical applications of prostate-specific antigen isoforms |
|
|
479 | (8) |
|
|
|
|
|
47 Radiographic anatomy of the prostate |
|
|
487 | (8) |
|
|
|
|
|
48 Transrectal and transperineal ultrasound-guided biopsy of the prostate |
|
|
495 | (6) |
|
|
|
|
|
49 Multivariate models for decreasing unnecessary biopsies for prostate cancer |
|
|
501 | (8) |
|
|
|
|
|
|
|
|
|
50 MR imaging (MRI) and MR spectroscopic imaging (MRSI) in the diagnosis and staging of prostate cancer |
|
|
509 | (10) |
|
|
|
|
|
51 Radioimmunoscintigraphy for imaging prostate cancer |
|
|
519 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
52 Clinical applications of immunoscintigraphy for prostate cancer |
|
|
531 | (12) |
|
|
|
|
|
|
|
53 Future directions in imaging prostate cancer |
|
|
543 | (8) |
|
|
|
|
|
54 Local therapy for prostate-specific antigen recurrence after definitive treatment |
|
|
551 | (14) |
|
|
|
|
|
55 Multivariate models for predicting pathologic stage |
|
|
565 | (4) |
|
|
|
|
|
56 Multivariate models for predicting biochemical recurrence after definitive local therapy |
|
|
569 | (10) |
|
|
|
|
|
57 Clinical interpretation of prostate biopsy reports |
|
|
579 | (6) |
|
|
|
|
|
58 Urine-based diagnostic tests for prostate cancer |
|
|
585 | (8) |
|
|
|
59 Diagnostic tests for prostate cancer: future directions |
|
|
593 | (12) |
|
|
|
|
|
SECTION 6 Treatment of early stage prostate cancer |
|
|
|
60 Coping with a diagnosis of prostate cancer: the patient and family perspective |
|
|
605 | (4) |
|
|
|
61 Decision-making for men with prostate cancer |
|
|
609 | (8) |
|
|
|
|
|
|
|
62 Reflections on prostate cancer: personal experiences of two urologic oncologists |
|
|
617 | (8) |
|
|
|
|
|
63 Role of the primary care professional in the care of the prostate cancer patient: a UK perspective |
|
|
625 | (8) |
|
|
|
64 Natural history and expectant management of prostate cancer |
|
|
633 | (6) |
|
|
|
|
|
65 Clinical trials comparing expectant management to definitive treatment of prostate cancer |
|
|
639 | (8) |
|
|
|
66 Practical and realistic lifestyle changes and supplements for the man concerned about prostate cancer: What do i tell my patients? |
|
|
647 | (22) |
|
|
|
67 Mortality trends in prostate cancer |
|
|
669 | (6) |
|
|
|
68 Preservation of sexual function after treatment for prostate cancer |
|
|
675 | (8) |
|
|
|
69 Quality-of-life instruments for prostate cancer |
|
|
683 | (4) |
|
|
|
|
|
70 Comparison of treatment modalities for localized prostate cancer using quality-of-life measures |
|
|
687 | (14) |
|
|
|
|
|
71 Anatomic considerations in radical prostatectomy |
|
|
701 | (14) |
|
|
|
|
|
72 Anatomic radical retropubic prostatectomy |
|
|
715 | (18) |
|
|
|
|
|
|
|
73 Radical retropubic prostatectomy: contemporary modifications |
|
|
733 | (8) |
|
|
|
|
|
74 Role of lymphadenectomy in prostate cancer |
|
|
741 | (6) |
|
|
|
|
|
|
|
|
|
75 Clinical management of rising prostate-specific antigen after radical retropubic prostatectomy |
|
|
747 | (8) |
|
|
|
|
|
76 Radical perineal prostatectomy |
|
|
755 | (10) |
|
|
|
|
|
77 Laparoscopic and robotic radical prostatectomy |
|
|
765 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
78 Vattikuti Institute prostatectomy: a robotic technique for the management of localized prostate cancer |
|
|
773 | (8) |
|
|
|
|
|
|
|
79 Role of surgery in the management of high-risk localized prostate cancer |
|
|
781 | (8) |
|
|
|
|
|
80 Prevention and management of complications associated with open radical retropubic prostatectomy |
|
|
789 | (10) |
|
|
|
81 External beam radiotherapy for the treatment of prostate cancer |
|
|
799 | (18) |
|
|
|
|
|
82 Brachytherapy for the treatment of prostate cancer |
|
|
817 | (14) |
|
|
|
|
|
|
|
|
|
83 High dose rate 192IR as monotherapy or as a boost: the new prostate brachytherapy |
|
|
831 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
84 MRi-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate |
|
|
841 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
85 Hyperthermia for treatment of localized prostate cancer |
|
|
849 | (6) |
|
|
|
86 Initial management of high risk early stage prostate cancer: radiation |
|
|
855 | (10) |
|
|
|
|
|
|
|
87 Management of biochemical recurrence following radiation therapy |
|
|
865 | (10) |
|
|
|
|
|
88 Cryotherapy as primary therapy for prostate cancer |
|
|
875 | (6) |
|
|
|
89 Cryotherapy as salvage therapy for prostate cancer |
|
|
881 | (6) |
|
|
|
|
|
90 Androgen deprivation for the treatment of prostate cancer: general principles |
|
|
887 | (8) |
|
|
|
|
|
91 Neoadjuvant and adjuvant hormonal therapies for prostate cancer: data review and patient perspectives |
|
|
895 | (14) |
|
|
|
92 Controversies in hormone treatment for prostate cancer |
|
|
909 | (6) |
|
|
|
93 Androgen deprivation therapy: the future |
|
|
915 | (14) |
|
|
|
|
|
94 The assessment and management of urinary incontinence in patients with prostate cancer |
|
|
929 | (12) |
|
|
|
|
|
|
|
95 Rehabilitation of sexual function following definitive treatment of local prostate cancer |
|
|
941 | (10) |
|
|
|
|
|
|
|
|
|
96 The limitations of evidence-based comparisons of treatment for localized prostate cancer |
|
|
951 | (8) |
|
|
|
SECTION 7 Treatment of locally advanced and metastatic prostate cancer |
|
|
|
97 Hormone therapy for prostate cancer: optimization and timing |
|
|
959 | (8) |
|
|
|
98 Intermittent androgen suppression for prostate cancer: rationale and clinical experience |
|
|
967 | (12) |
|
|
|
|
|
99 Antiandrogen withdrawal syndromes: pathophysiology and clinical implications |
|
|
979 | (10) |
|
|
|
|
|
|
|
|
|
100 Chemotherapy for advanced prostate cancer |
|
|
989 | (16) |
|
|
|
|
|
101 Radiotherapy for the treatment of locally advanced and metastatic prostate cancer |
|
|
1005 | (20) |
|
|
|
|
|
|
|
102 Use of bisphosphonates in the management of osseous metastases |
|
|
1025 | (6) |
|
|
|
|
|
103 Managing the complications of advanced prostate cancer |
|
|
1031 | (12) |
|
|
|
104 Principles of palliative care and psychosocial support of the metastatic prostate cancer patient |
|
|
1043 | (6) |
|
|
|
105 The promise of immunotherapy in prostate cancer: from concept to reality |
|
|
1049 | (12) |
|
|
|
|
|
|
| Index |
|
1061 | |
More info about Taylor & Francis e-books